SKU: N096  / 
    CAS Number: 1691240-78-4

    Nafithromycin

    ₩421,492.50

    Nafithromycin is a ketolide antibiotic, which are fourth generation macrolides derived from Erythromycin A. Nafithromycin can be used in research related to bacterial infections. Its structure includes a unique amidoxime core with a 2-pyridine-1,3,4-thiadiazole biaryl tether separated by a non-flexible four-atom spacer containing a cis double bond and a chiral methyl. It was developed by Wockhardt Ltd in 2024 and represents India's first indigenous macrolide antibiotic. It has received Qualified Infectious Disease Product (QIDP) designation from the US FDA. It is used in infectious disease and virology research, susceptibility testing, and to study antimicrobial resistance and ribosome binding.

    Mechanism of Action Nafithromycin binds to domains II and V of bacterial 23S rRNA and the peptidyl transferase center of the 50S ribosomal subunit, thereby inhibiting protein synthesis.
    Microbiology Applications Ketolides are designed to overcome issues with bacterial resistance via its keto function at C3, after replacement of the l-cladinose sugar moiety resulting in a broader spectrum of activity. The lack of the sugar moiety is believed to reduce the potential for inducible macrolide resistance. Nafithromycin's unique structure helps to overcome all three of the macrolide resistance mechanisms: ermB, efflux and ribosomal protein mutations (in S. pneumoniae).
    Eukaryotic Cell Culture Applications Cell-based assays for Nafithromycin for susceptibility testing applications use the broth microdilution method.
    Molecular Formula C42H62N6O11S
    References

    Bhavsar S (2023) WCK 4873 (INN: Nafithromycin): Structure–activity relationship (SAR) identifying a novel lactone ketolide with activity against Streptococcus pneumoniae (SPN) and Streptococcus pyogenes (SPY). Results in Chem. 5:100757

    Kohlhoff S and Hammerschlag MR (2021) In vitro activity of Nafithromycin (WCK 4873) against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 65(9):e0058521 PMID: 34152817

    Kumar D (2025) Nafithromycin: A potential ketolide antibiotic for combating antimicrobial resistance in community-acquired bacterial pneumonia Next Res. 2(3):100592

    Sen D (2025) Nafithromycin chemistry and mode of action. Eur. J. Biomed. Pharm. Sci. 12 (2): 300-305